Formulation and Evaluation of Metformin Hydrochloride Immediate-Release Tablets Using Different Pharmaceutical Binders

Metformin Hydrochloride (MetHCl), a biguanide derivative, is the first-line oral antidiabetic agent for the management of type 2 diabetes mellitus. It acts primarily by reducing hepatic glucose production and increasing peripheral insulin sensitivity. With its high water solubility (>300 mg/mL), short biological half-life (4–6 hours), and high therapeutic dose requirement (500–1000 mg per tablet), Metformin poses unique formulation challenges, particularly in achieving uniform drug release and adequate mechanical strength simultaneously. [1, 2]Tablets are the most preferred oral solid dosage forms, accounting for over 70% of all pharmaceutical formulations due to their stability, ease of manufacture, accurate dosing, and patient compliance. During tablet formulation by wet or dry granulation, pharmaceutical binders play a critical role by providing cohesive strength to the powder blend, forming granules of adequate size and flowability, and ultimately determining the mechanical integrity and dissolution behavior of the final tablet. [3]Binders can be classified into three broad categories: (a) natural binders such as starch, gum acacia, and gelatin; (b) synthetic binders such as polyvinylpyrrolidone (PVP); and (c) semi-synthetic binders such as hydroxypropyl methylcellulose (HPMC) and carboxymethyl cellulose sodium (SCMC). The physico-chemical properties of these binders — including molecular weight, viscosity, hydrophilicity, and swelling behavior — profoundly influence tablet hardness, friability, disintegration time, and drug dissolution. [4, 5]Although extensive reviews exist on the role of binders in tablet formulations, limited experimental comparative data are available specifically for Metformin HCl 500 mg immediate-release tablets under identical processing conditions. The present study was therefore designed to formulate and systematically evaluate three batches of Metformin HCl IR tablets using starch, PVP K30, and HPMC E5 as representative natural, synthetic, and semi-synthetic binders respectively, and to identify the most suitable binder for achieving optimal tablet properties and drug release. [6]Type 2 Diabetes Mellitus represents one of the most significant global public health challenges, characterized by chronic hyperglycemia resulting from insulin resistance and impaired insulin secretion. The prevalence of this metabolic disorder has increased dramatically over the past few decades due to sedentary lifestyles, dietary changes, and genetic predisposition. Effective glycemic control remains the cornerstone of diabetes management, and oral hypoglycemic agents play a vital role in achieving this therapeutic goal. Among these agents, Metformin Hydrochloride has emerged as the first-line pharmacological treatment due to its well-established efficacy, safety profile, and additional benefits such as weight neutrality and cardiovascular protection.Metformin Hydrochloride belongs to the biguanide class of antidiabetic drugs and exerts its primary action by inhibiting hepatic gluconeogenesis, thereby reducing glucose production in the liver. Additionally, it enhances peripheral glucose uptake in skeletal muscles and improves insulin sensitivity without causing significant hypoglycemia. Despite its therapeutic advantages, Metformin presents unique formulation challenges due to its physicochemical properties. It is highly water-soluble (greater than 300 mg/mL), has a relatively short biological half-life of approximately 4–6 hours, and is administered in high doses (typically 500–1000 mg per tablet). These characteristics necessitate careful formulation strategies to ensure adequate mechanical strength of tablets while maintaining rapid drug release for immediate therapeutic action.Among the various oral dosage forms, tablets remain the most widely used and preferred due to their convenience, stability, accurate dosing, and cost-effectiveness. It is estimated that tablets constitute more than 70% of all pharmaceutical dosage forms available in the market. The manufacturing of tablets involves multiple unit operations including blending, granulation, drying, lubrication, and compression. Each of these steps plays a critical role in determining the final product quality. In particular, the selection of excipients, especially binders, is crucial as they significantly influence the physicomechanical properties and drug release behavior of tablets.

Pharmaceutical binders are essential excipients that impart cohesiveness to powder blends, facilitating the formation of granules during granulation and ensuring adequate mechanical strength of the compressed tablets. Binders function by promoting interparticulate adhesion through mechanisms such as plastic deformation, liquid bridging, and solid bridge formation. Based on their origin and chemical nature, binders can be broadly classified into three categories: natural binders (e.g., starch, gum acacia, gelatin), synthetic binders (e.g., polyvinylpyrrolidone), and semi-synthetic binders (e.g., hydroxypropyl methylcellulose). Each class of binder exhibits distinct physicochemical properties, including molecular weight, viscosity, solubility, and swelling behavior, which in turn influence tablet hardness, friability, disintegration time, and dissolution profile.The choice of binder is particularly critical in the formulation of immediate-release (IR) tablets. While strong binders improve tablet hardness and reduce friability, they may also retard disintegration and delay drug release. Conversely, weak binders may facilitate rapid disintegration but result in poor mechanical strength, leading to handling and packaging issues. Therefore, achieving an optimal balance between mechanical integrity and rapid drug release is a key challenge in tablet formulation. This becomes even more significant in the case of high-dose drugs like Metformin, where the large drug load can compromise tablet compactibility and uniformity.

Among commonly used binders, starch is a natural polymer known for its swelling and disintegrating properties, making it suitable for immediate-release formulations. Polyvinylpyrrolidone K30 (PVP K30), a synthetic polymer, is widely used due to its excellent binding properties and ability to form strong, uniform granules. However, its high binding efficiency may sometimes lead to slower disintegration. Hydroxypropyl Methylcellulose E5 (HPMC E5), a semi-synthetic cellulose derivative, exhibits both binding and gel-forming properties, which can influence drug release kinetics depending on its concentration and viscosity grade.Although several studies have investigated the role of binders in tablet formulation, there is limited experimental data directly comparing natural, synthetic, and semi-synthetic binders under identical formulation and processing conditions, particularly for Metformin Hydrochloride immediate-release tablets. Understanding the comparative performance of these binders is essential for rational formulation design and optimization.Therefore, the present study was undertaken with the objective of formulating and evaluating immediate-release tablets of Metformin Hydrochloride using three different binders—starch, PVP K30, and HPMC E5—representing natural, synthetic, and semi-synthetic categories, respectively. The study focuses on assessing the impact of these binders on pre-compression parameters (flow properties and compressibility), post-compression characteristics (hardness, friability, disintegration), and in vitro drug release behavior. By systematically analyzing these parameters, the study aims to identify the most suitable binder for achieving optimal tablet performance in terms of both mechanical strength and drug release, thereby contributing to the development of effective and reliable immediate-release formulations.

2. MATERIALS AND METHODS

2.1 Materials

Metformin Hydrochloride IP (gift sample from Cipla Ltd., Mumbai), Starch IP (Hi-Media Laboratories), PVP K30 (Loba Chemie Pvt. Ltd.), HPMC E5 (Colorcon Asia), Microcrystalline Cellulose (MCC) PH-101 (Hi-Media), Croscarmellose Sodium (CCS) (Loba Chemie), Magnesium Stearate IP (Hi-Media), Talc IP (Hi-Media), Isopropyl Alcohol (IPA) (Loba Chemie). All other chemicals and reagents used were of analytical grade.

2.2 Preformulation Studies

Preformulation studies were conducted on Metformin HCl including identification by melting point determination, drug-excipient compatibility study by FTIR spectroscopy, and determination of aqueous solubility. The drug was found to be freely soluble in water (320.4 ± 4.2 mg/mL at 25°C), confirming its high aqueous solubility.

2.3 Formulation of Tablets

Three tablet formulations (F1, F2, and F3) were prepared by the wet granulation technique, each containing 500 mg Metformin HCl per tablet. The composition is presented in Table 1.

Table 1: Formulation Composition of Metformin HCl Tablets (per tablet, mg)

The granulation solvent used was isopropyl alcohol (IPA). The binder was dissolved/dispersed in IPA (10% w/v solution) and added to the dry blend. The wet mass was passed through a 16-mesh sieve, dried at 50°C for 2 hours, and passed through a 20-mesh sieve to obtain granules. The lubricants were added and mixed for 5 minutes before compression on a 10-station rotary tablet machine using 13 mm flat-faced punches.

Immediate-release tablets were prepared by wet granulation technique. Three formulations (F1–F3) were designed using different binders: starch, PVP K30, and HPMC E5.

Procedure:

1. Accurately weighed quantities of MetHCl, MCC PH-101, and CCS were passed through a #40 sieve and mixed uniformly in a mortar.
2. The binder solution (10% w/v) was prepared separately using IPA as solvent.
3. The binder solution was gradually added to the powder blend with continuous mixing to obtain a coherent wet mass.
4. The wet mass was passed through a #16 sieve to form granules.
5. Granules were dried in a hot air oven at 50°C for 2 hours.
6. Dried granules were resized using #20 sieve.
7. Lubricants (magnesium stearate and talc) were added and mixed gently for 5 minutes.
8. The final blend was compressed into tablets using a 10-station rotary compression machine fitted with 13 mm flat-faced punches.

2.4 Pre-Compression Evaluation of Granules

The prepared granules were evaluated for angle of repose (fixed funnel method), bulk density, tapped density (USP tapping device), Carr's index (compressibility index), and Hausner's ratio as per standard pharmacopeial procedures.

The prepared granules were evaluated for flow and compressibility properties.

2.4.1 Angle of Repose

Measured by fixed funnel method. The angle was calculated using:

tan θ = h/r

2.4.2 Bulk Density

Bulk density was determined by pouring granules into a graduated cylinder and measuring volume.

2.4.3 Tapped Density

Determined using USP tapping apparatus after 100 taps.

2.4.4 Carr’s Index

Calculated using formula:

Carr’s Index (%) = [(Tapped density − Bulk density) / Tapped density] × 100

2.4.5 Hausner’s Ratio

Hausner’s Ratio = Tapped density / Bulk density

These parameters were evaluated to assess suitability of granules for compression.

2.5 Post-Compression Evaluation of Tablets

Compressed tablets were evaluated for the following parameters: (i) Hardness – Monsanto hardness tester (n = 6); (ii) Thickness – Vernier calipers (n = 10); (iii) Friability – Roche friabilator at 25 rpm for 4 min (n = 20, limit ≤ 1.0%); (iv) Weight variation – analytical balance (n = 20, as per IP); (v) Disintegration time – USP disintegration apparatus in water at 37 ± 0.5°C; (vi) Content uniformity – UV spectrophotometry at 232 nm.

Compressed tablets were evaluated according to pharmacopeial standards.

2.5.1 Hardness

Measured using Monsanto hardness tester (n = 6).

2.5.2 Thickness

Determined using Vernier calipers (n = 10).

2.5.3 Friability

Evaluated using Roche friabilator at 25 rpm for 4 minutes (n = 20). Percentage weight loss was calculated.

2.5.4 Weight Variation

Twenty tablets were weighed individually and compared with average weight as per IP specifications.

2.5.5 Disintegration Test

Performed using USP disintegration apparatus in distilled water at 37 ± 0.5°C.

2.5.6 Drug Content

Tablet powder equivalent to 100 mg drug was dissolved, filtered, and analyzed at 232 nm using UV spectrophotometer.

2.6 In Vitro Dissolution Study

Dissolution was carried out using USP Type II (paddle) apparatus in 900 mL of phosphate buffer pH 6.8 at 37 ± 0.5°C and 50 rpm. Samples (5 mL) were withdrawn at 10, 20, 30, 45, and 60 minutes, filtered, and analyzed spectrophotometrically at 232 nm. Fresh buffer was replaced after each withdrawal to maintain sink conditions. All experiments were performed in triplicate (n = 6).

Dissolution testing was performed using USP Type II (paddle apparatus). The study was conducted in 900 mL phosphate buffer pH 6.8 at 37 ± 0.5°C with paddle speed of 50 rpm.

At predetermined intervals (10, 20, 30, 45, 60 minutes), 5 mL samples were withdrawn and replaced with fresh medium to maintain sink conditions. Samples were filtered and analyzed spectrophotometrically at 232 nm. Cumulative percentage drug release was calculated.

3. RESULTS AND DISCUSSION

3.1 Preformulation Studies

Melting point of Metformin HCl was found to be 223 ± 1°C (reported: 220–226°C), confirming purity of the drug. FTIR spectra of drug-excipient physical mixtures showed no significant shifting or disappearance of major characteristic peaks of Metformin HCl (N-H stretch at 3363 cm?¹, C-N stretch at 1626 cm?¹), indicating absence of physicochemical incompatibility with the selected excipients.

3.2 Pre-Compression Parameters

Results of granule evaluation are presented in Table 2. All three formulations showed angle of repose values below 30° (F1: 26.4 ± 0.8°, F2: 24.2 ± 0.6°, F3: 25.8 ± 0.7°), indicating good flow properties. Carr's index values were in the range of 12–16%, suggesting satisfactory compressibility of all granules. F2 (PVP K30) granules showed the best flowability, attributed to PVP's ability to form smooth, spherical granules.

Table 2: Pre-compression Granule Evaluation Parameters (Mean ± SD, n=3)

3.3 Post-Compression Evaluation

Post-compression results are summarized in Table 3. Tablet hardness was highest for F2 (7.8 ± 0.4 kg/cm²), attributed to PVP's strong plastic deformation and adhesive binding. F1 (starch) showed lower hardness (5.2 ± 0.3 kg/cm²) due to starch's relatively brittle fracture behavior. All formulations showed friability below 1.0% (IP limit) and passed the weight variation test. Disintegration was fastest for F1 (4.2 ± 0.3 min) as starch granules promote rapid water penetration and swelling, leading to rapid disintegration. F2 showed the slowest disintegration (7.6 ± 0.5 min) due to the dense, hydrated polymer matrix formed by PVP. Content uniformity was within 90–110% for all formulations, complying with USP requirements.

Table 3: Post-compression Evaluation of Metformin HCl Tablets (Mean ± SD)

3.4 In Vitro Dissolution Study

Cumulative percent drug release profiles are shown in Table 4. F1 (starch) exhibited the highest drug release of 98.4 ± 1.3% at 60 minutes, consistent with its rapid disintegration behavior and hydrophilic nature of starch. F2 (PVP K30) showed 95.6 ± 1.5% drug release at 60 min — though slightly lower, it still falls within the IP specification for Metformin HCl tablets (NLT 80% in 45 min). F3 (HPMC E5) demonstrated more gradual release (93.2 ± 1.8% at 60 min), reflecting the gel-forming tendency of HPMC that creates a diffusion barrier. All formulations exceeded the pharmacopeial requirement of NLT 80% drug release within 45 minutes.

Table 4: Cumulative % Drug Release from Metformin HCl Tablets (Mean ± SD, n=6)